Gastroenterology
Volume 134, Issue 7 , Pages 1890-1899 , June 2008

Hepatocellular Carcinoma Is Associated With an Increased Risk of Hepatitis B Virus Recurrence After Liver Transplantation

  • Luciana C. Faria

      Affiliations

    • INSERM, U 785, Villejuif, France
    • Federal University of Minas Gerais, Faculty of Medicine, Department of Internal Medicine, Belo Horizonte, MG, Brazil
    • ANRS HP EP 01 cccDNA, Paris, France
    • ,
  • Michelle Gigou

      Affiliations

    • INSERM, U 785, Villejuif, France
    • Université Paris-Sud, UMR-S 785, Villejuif, France
    • ANRS HP EP 01 cccDNA, Paris, France
    • ,
  • Anne M. Roque–Afonso

      Affiliations

    • INSERM, U 785, Villejuif, France
    • Université Paris-Sud, UMR-S 785, Villejuif, France
    • AP-HP Hopital Paul Brousse, Centre Hepato-Billaire, Villejuif, France
    • ,
  • Mylene Sebagh

      Affiliations

    • INSERM, U 785, Villejuif, France
    • Université Paris-Sud, UMR-S 785, Villejuif, France
    • ,
  • Bruno Roche

      Affiliations

    • INSERM, U 785, Villejuif, France
    • AP-HP Hopital Paul Brousse, Centre Hepato-Billaire, Villejuif, France
    • Université Paris-Sud, UMR-S 785, Villejuif, France
    • ,
  • Guillaume Fallot

      Affiliations

    • INSERM, U 785, Villejuif, France
    • Université Paris-Sud, UMR-S 785, Villejuif, France
    • ,
  • Teresa C.A. Ferrari

      Affiliations

    • Federal University of Minas Gerais, Faculty of Medicine, Department of Internal Medicine, Belo Horizonte, MG, Brazil
    • ,
  • Catherine Guettier

      Affiliations

    • INSERM, U 785, Villejuif, France
    • Université Paris-Sud, UMR-S 785, Villejuif, France
    • ,
  • Elisabeth Dussaix

      Affiliations

    • INSERM, U 785, Villejuif, France
    • Université Paris-Sud, UMR-S 785, Villejuif, France
    • ,
  • Denis Castaing

      Affiliations

    • INSERM, U 785, Villejuif, France
    • AP-HP Hopital Paul Brousse, Centre Hepato-Billaire, Villejuif, France
    • ,
  • Christian Brechot

      Affiliations

    • INSERM, U 785, Villejuif, France
    • Université Paris-Sud, UMR-S 785, Villejuif, France
    • ,
  • Didier Samuel

      Affiliations

    • INSERM, U 785, Villejuif, France
    • Université Paris-Sud, UMR-S 785, Villejuif, France
    • AP-HP Hopital Paul Brousse, Centre Hepato-Billaire, Villejuif, France
    • Corresponding Author InformationAddress requests for reprints to: Didier Samuel, MD, Prof, Centre Hepato-Biliaire, Hôpital Paul Brousse, 94800 Villejuif, France. fax: (33) 1 45 59 38 57.

Received 2 August 2007 ,Accepted 21 February 2008.

References 

  1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745
  2. Adam R, McMaster P, O'Grady JG, et al. European Liver Transplantation Association Evolution of liver transplantation in Europe: report of the European liver transplant registry. Liver Transpl. 2003;9:1231–1243
  3. Camci C, Gurakar A, Rose J, et al. Liver transplantation for hepatitis B in the United States. Transplant Proc. 2005;37:4350–4353
  4. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–1847
  5. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology. 1996;24:1327–1333
  6. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology. 2000;32:1189–1195
  7. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998;28:585–589
  8. Han SHB, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000;6:741–748
  9. Marzanno A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001;34:903–910
  10. Roche B, Feray C, Gigou M, et al. HBV-DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology. 2003;38:86–95
  11. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 2005;11:716–732
  12. Szmuness W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol. 1978;24:40–69
  13. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus (A prospective study of 22,707 men in Taiwan). Lancet. 1981;2:1129–1133
  14. Brechot C. Hepatitis B and C viruses and primary liver cancer. Baillieres Clin Gastroenterol. 1996;10:335–373
  15. Idilman R, De Maria N, Colantoni A, et al. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepat. 1998;5:285–299
  16. Sun Z, Lu P, Gail MH, et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology. 1999;30:379–383
  17. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917
  18. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97:265–272
  19. Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  20. Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis. 2006;194:594–599
  21. Raimondo G, Burk RD, Lieberman HM, et al. Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma. Virology. 1988;166:103–112
  22. Wang WL, London WT, Feitelson MA. Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res. 1991;51:4971–4977
  23. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells. Cell. 1986;47:451–460
  24. Newbold JE, Xin H, Tencza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromossomes. J Virol. 1995;69:3350–3357
  25. Zanella I, Rossini A, Domenighini D, et al. Real-time quantitation of hepatitis B virus (HBV) DNA in tumorous and surrounding tissue from patients with hepatocellular carcinoma. J Med Virol. 2002;68:494–499
  26. Pollicino T, Squadrito G, Cerenzia G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126:102–110
  27. Wong DK, Yuen MF, Poon RT, et al. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol. 2006;45:553–559
  28. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–1758
  29. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:728–729
  30. Hochberger S, Althof D, Gallegos de Schrott R, et al. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS Taqman System. J Clin Virol. 2006;35:373–380
  31. Petit MA, Dubanchet S, Capel F. A monoclonal antibody specific for the hepatocyte receptor binding site on hepatitis B virus. Mol Immunol. 1989;26:531–537
  32. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transíplantation in HBsAg-positive patients. Lancet. 1991;337:813–815
  33. Neff GW, O'Brien CB, Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl. 2004;10:1372–1378
  34. Marzanno A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B recurrence. Liver Transpl. 2005;11:402–409
  35. Wong PYN, McPeake JR, Portmann B, et al. Clinical course and survival after liver transplantation for hepatitis B virus infection complicated by hepatocellular carcinoma. Am J Gastroenterol. 1995;90:29–34
  36. Mazzaferro V, Regalia E, Montalto F, et al. Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis (Primary hepatocellular carcinoma is not a predictor for HBV recurrence. The European Cooperative Study Group on Liver Cancer and Transplantation). Liver. 1996;16:117–122
  37. Steinmüller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35:1528–1535
  38. Wong SN, Reddy KR, Keeffe EB, et al. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl. 2007;13:334–342
  39. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy (Report of a prospective study). Gastroenterology. 1991;100:182–188
  40. Markovic S, Drozina G, Vovk M, et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy (A prospective study in 305 patients). Hepatogastroenterology. 1999;46:2925–2930

 Supported by the French National Agency for Research on AIDS and Viral Hepatitis (ANRS), ANRS HB EP 01 cccDNA, who is the sponsor of this trial, and by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; to L.C.F.), Brazil.Conflicts of interest: None of the authors have any potential financial conflicts of interest related to this paper.

PII: S0016-5085(08)00330-2

doi: 10.1053/j.gastro.2008.02.064

Gastroenterology
Volume 134, Issue 7 , Pages 1890-1899 , June 2008

Article Tools

* Image Usage & Resolution